This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.
The investigators propose to evaluate the feasibility of using a novel small molecule PET radiotracer, DCFPyL to target prostate cancer prostate-specific membrane antigen (PSMA). PSMA is a well studied cell surface marker of prostate cancer with increased expression associated with higher tumor grade and advanced metastatic tumors. More specifically it is associated with a higher Gleason score and there is evidence it can serve as a potential marker for prostate tumor carcinogenesis, progression and as a AR signaling surrogate marker of ADT response. This small molecule PET radiotracer specifically targeting an important prostate specific marker of AR signaling dynamics following ADT, tumor progression and metastatic potential warrants validation as an in-vivo non-invasive imaging biomarker for PSMA expression and prostate cancer detection.
Men 18 years of age or greater with recently diagnosed prostate cancer with planned radiation and ADT.
Key inclusion criteria (the entire list of inclusion and exclusion criteria will appear later in section 4 of the protocol)
Newly diagnosed prostate cancer pathologically proven by prostate biopsy Prostate biopsy histology grade ≥ Gleason 8-10 Patients considered as candidates for and medically fit to undergo radiation and ADT At least 10 days after most recent prostate biopsy
Exclusion Criteria:
Prior pelvic external beam radiation therapy or brachytherapy Chemotherapy for prostate cancer Hormone deprivation therapy Investigational therapy for prostate cancer Hemorrhagic cystitis or active prostatitis
